IMDX (Insight Molecular Diagnostics) PB Ratio: (As of Jun. 29, 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.32
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Insight Molecular Diagnostics's share price is $5.32. Insight Molecular Diagnostics's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.33. Hence, Insight Molecular Diagnostics's PB Ratio of today is .

The historical rank and industry rank for Insight Molecular Diagnostics's PB Ratio or its related term are showing as below:

During the past 13 years, Insight Molecular Diagnostics's highest PB Ratio was 89.74. The lowest was 0.48. And the median was 2.11.

IMDX's PB Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.04
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Insight Molecular Diagnostics's average Book Value Per Share Growth Rate was -192.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Insight Molecular Diagnostics was 103.30% per year. The lowest was -41.00% per year. And the median was 16.40% per year.

Back to Basics: PB Ratio


Insight Molecular Diagnostics  (NAS:IMDX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Insight Molecular Diagnostics PB Ratio Related Terms


Insight Molecular Diagnostics PB Ratio Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics PB Ratio Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.07 1.11 1.01 0.00 0.00

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.57 79.47 0.00 0.00 0.00

IMDX vs XGN, BDSX, BNR: PB Ratio Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's PB Ratio falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Insight Molecular Diagnostics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=5.32/-0.331
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.32 is trading 322.2% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • PB Ratio:
  • GF Value™: $1.26 vs. price of $5.32 (322.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.32
Price
$1.26
GF Value